{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-148067","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.624659+00:00","generated_at":"2026-06-25T18:02:07.121845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi Bioscience Q1 2022: FYARRO sales $2.3M; net loss $13.9M; first patient dosed in PRECISION 1 trial","bullets":["Net product sales of FYARRO were $2.3M for partial first quarter since launch in Feb 2022.","Net loss for Q1 2022 was $13.9M vs $5.5M in Q1 2021; operating expenses $16.1M vs $4.2M.","Cash and equivalents $129.8M as of Mar 31, 2022, expected to fund operations into 2024.","First patient dosed in PRECISION 1 Phase 2 tumor-agnostic trial for TSC1/TSC2 altered tumors; initial data expected H1 2023.","Permanent J-code (J9331) for FYARRO granted, effective Jul 1, 2022; partnerships with Foundation Medicine and Tempus for trial enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-148067","json":"https://secwatch.observer/filing/0001193125-22-148067.json","markdown":"https://secwatch.observer/filing/0001193125-22-148067.md","text":"https://secwatch.observer/filing/0001193125-22-148067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522148067/0001193125-22-148067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522148067/d326757d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:02:07.121845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}